Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2017

  • ID: 4429830
  • Report
  • 163 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Alteogen Inc
  • Biocon Ltd
  • Coherus BioSciences Inc
  • Genor BioPharma Co Ltd
  • Mycenax Biotech Inc
  • MORE
Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2017, provides an overview of the Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline landscape.

Ankylosing spondylitis is a type of arthritis that affects the spine. Ankylosing spondylitis symptoms include pain and stiffness from the neck down to the lower back. The spine's bones (vertebrae) may grow or fuse together, resulting in a rigid spine. These changes may be mild or severe, and may lead to a stooped-over posture.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Ankylosing Spondylitis (Bekhterev's Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 5, 5, 9, 1, 13, 7 and 3 respectively.

Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).
  • The pipeline guide reviews pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ankylosing Spondylitis (Bekhterev's Disease) (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Alteogen Inc
  • Biocon Ltd
  • Coherus BioSciences Inc
  • Genor BioPharma Co Ltd
  • Mycenax Biotech Inc
  • MORE
Introduction

Ankylosing Spondylitis (Bekhterev's Disease) - Overview

Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Ankylosing Spondylitis (Bekhterev's Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Ankylosing Spondylitis (Bekhterev's Disease) - Companies Involved in Therapeutics Development

AbbVie Inc

Adello Biologics LLC

Allergan Plc

Alteogen Inc

Amgen Inc

Biocad

Biocon Ltd

Bionovis SA

Celgene Corp

Coherus BioSciences Inc

Fresenius SE & Co KGaA

Galapagos NV

Genor BioPharma Co Ltd

Immunwork Inc

Innovent Biologics Inc

Mycenax Biotech Inc

Nichi-Iko Pharmaceutical Co Ltd

Novartis AG

Oncobiologics Inc

Protalix BioTherapeutics Inc

Reliance Life Sciences Pvt Ltd

Sandoz International GmbH

Shanghai Pharmaceutical Co Ltd

Sun Pharma Advanced Research Company Ltd

UCB SA

Xbrane Biopharma AB

Ankylosing Spondylitis (Bekhterev's Disease) - Drug Profiles

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

apremilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCD-085 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimekizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

certolizumab pegol biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNX-114 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNX-514 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etanercept biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

filgotinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

golimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

golimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HEISCO-III-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infliximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infliximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infliximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infliximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infliximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infliximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

infliximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

risankizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

secukinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TE-2122 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TE-2158 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

thalidomide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tildrakizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

upadacitinib tartrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTP-43742 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects

Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products

Ankylosing Spondylitis (Bekhterev's Disease) - Product Development Milestones

Featured News & Press Releases

Nov 06, 2017: Novartis seeks leadership with Cosentyx showing no radiographic progression in ankylosing spondylitis at 4 years

Oct 30, 2017: Novartis to present first of its kind evidence for Cosentyx on potential to maintain mobility in patients with AS and PsA

Jun 15, 2017: Novartis Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years

Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib

Nov 14, 2016: Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain

Oct 31, 2016: Novartis Wins Prestigious Prix Galien Foundation Award, Cosentyx as Best Biotechnology Product

Sep 28, 2016: NICE Issues Positive Final Appraisal Determination For Cosentyx (Secukinumab)

Sep 12, 2016: Innovent IBI303 to Initiate Pivotal Clinical Comparability studies with Adalimumab

Aug 04, 2016: NICE draft guidance recommends new drug for people with ankylosing spondylitis

Aug 04, 2016: NICE Issues Positive Final Appraisal Determination For Cosentyx

Jun 08, 2016: Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016

Apr 27, 2016: COSENTYX - first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada

Jan 20, 2016: Diplomat Announces COSENTYX Availability for the Treatment of Two New Indications

Jan 15, 2016: Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US

Dec 23, 2015: Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by AbbVie Inc, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Adello Biologics LLC, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Allergan Plc, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Alteogen Inc, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Amgen Inc, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocad, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Biocon Ltd, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Bionovis SA, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Celgene Corp, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Coherus BioSciences Inc, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Fresenius SE & Co KGaA, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Galapagos NV, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Genor BioPharma Co Ltd, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Immunwork Inc, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Innovent Biologics Inc, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Mycenax Biotech Inc, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Nichi-Iko Pharmaceutical Co Ltd, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Novartis AG, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Oncobiologics Inc, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Protalix BioTherapeutics Inc, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sandoz International GmbH, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by UCB SA, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Pipeline by Xbrane Biopharma AB, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Dormant Projects, H2 2017 (Contd..1), H2 2017

Ankylosing Spondylitis (Bekhterev's Disease) - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Ankylosing Spondylitis (Bekhterev's Disease), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Adello Biologics LLC
  • Allergan Plc
  • Alteogen Inc
  • Amgen Inc
  • Biocad
  • Biocon Ltd
  • Bionovis SA
  • Celgene Corp
  • Coherus BioSciences Inc
  • Fresenius SE & Co KGaA
  • Galapagos NV
  • Genor BioPharma Co Ltd
  • Immunwork Inc
  • Innovent Biologics Inc
  • Mycenax Biotech Inc
  • Nichi-Iko Pharmaceutical Co Ltd
  • Novartis AG
  • Oncobiologics Inc
  • Protalix BioTherapeutics Inc
  • Reliance Life Sciences Pvt Ltd
  • Sandoz International GmbH
  • Shanghai Pharmaceutical Co Ltd
  • Sun Pharma Advanced Research Company Ltd
  • UCB SA
  • Xbrane Biopharma AB
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll